Skip banner and top navigation
NHLBI Logo and Link
National Heart, Lung, and Blood Institute: People, Science, Health
 HOME  SITE INDEX  CONTACT US
  
  Patient Recruitment - Blood Diseases and Cancer
TIPS     ADVANCED SEARCH
 

Research Studies        
Autologous NK cell infusions in treatment resistant Cancer   Stem Cell Transplant for Treatment of Metastatic Renal Cell (Kidney) Cancer

Cancer Research Study

Autologous NK cell infusions in treatment resistant Cancer

If you (or someone you know) has metastatic cancer of the lung, prostate, colon, rectum, kidney, pancreas or malignant melanoma that is not responding to standard treatments, you may be able to participate in our clinical trial designed to evaluate the safety of a new type of cell therapy. Specifically, we are testing the safety and tolerability of the infusion of a type of your own white blood cells called NK cells.

In this research project, your NK cells will be collected, reproduced to large numbers in the laboratory and then be given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.

To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov


 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Cancer Research Study

Stem Cell Transplant for Treatment of Metastatic Renal Cell (Kidney) Cancer

If you have been diagnosed with metastatic renal cell (kidney) cancer, you may be eligible for a stem cell transplant procedure here at the National Institutes of Health (NIH). Under evaluation is whether graft-versus-tumor effects can be generated against renal cell tumors. You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.

We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.

To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information
 

 
 
Spacer

NHLBI HOME · ACCESSIBILITY INFORMATION · NHLBI AT THE CLINICAL CENTER · PRIVACY STATEMENT · WEB TECHNICAL CONTACT